US FDA pauses Gilead trials testing experimental HIV pill combination
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
FDA clinical hold a 'blow to Gilead Sciences (GILD) HIV pipeline - Oppenheimer
June 10, 2025 11:14 AM UTCOppenheimer analyst Hartaj Singh reiterated an Outperform rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD) but said the clinical hold is a 'blow' to the company's HIV pipeline.
The analyst commented, "This morning, Gilead announced that the FDA had put ongoing GS-4182+GS-1720... More
